Latest news
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial - StocktwitsStocktwits · Fri, 07 Aug 2026 15:54:57 GMTMicot Pharma's MT200605 Achieves Primary Endpoint in Phase II Trial, Novel Integrated Multi-stage Neuroprotection Mechanism to Be Presented at WSC 2026 - FinancialContentFinancialContent · Fri, 07 Aug 2026 08:36:00 GMT